세계의 자가면역질환 진단 시장 규모는 2023년 39억 달러에 달했습니다. 향후 IMARC Group은 시장이 2032년까지 64억 달러에 이를 전망이고, 예측 기간 동안 복합 연간 성장률(CAGR)은 5.4%가 될 것으로 예측했습니다. 자가면역질환의 이환율 증가, 보험계약 매출 증가, EMR 이용 확대 등이 시장을 견인하는 주요 요인입니다.
자가면역질환은 면역체계가 신체의 세포, 조직, 장기를 공격하는 질환군입니다. 전신성 홍반성 루푸스(SLE), 다발성 경화증, 류마티스 성 관절염, i 형 당뇨병 등 다양한 병리에 의해 유발됩니다. 권태감, 관절통이나 굳어짐, 피진, 발열, 소화 불량 등을 동반합니다. 또한 장기와 조직에 손상을 주어 호흡 곤란, 장기 부전 또는 사망과 같은 심각한 증상을 일으킬 수 있습니다. 상세한 병력 청취, 신체진찰, 특이적 항체를 검출하기 위한 혈액검사, 손상이나 염증을 찾기 위한 영상검사, 이환된 조직을 현미경으로 조사하기 위한 생검 등 다양한 접근법을 조합하여 진단합니다.
자가면역 질환 환자 수의 급증과 이러한 병리를 일으키기 쉬운 고령화 인구 증가는 세계의 자가면역 질환 진단 수요를 촉진하는 주요 요인 중 하나입니다. 또한, 자가면역 질환, 증상, 진단, 치료 옵션의 용이한 가용성에 대한 의식이 높아지면서 시장 성장을 가속하고 있습니다. 게다가 자가면역질환의 진단과 치료에 대한 경제적 지원을 제공하고 의료비 전체를 삭감하는 건강보험의 도입이 확대되고 있는 것도 시장에 긍정적인 영향을 미치고 있습니다. 이 외에도 자가면역질환 연구 및 새로운 치료법 개발을 위한 연구개발(R&D) 프로젝트에 자금을 제공하는 국가도 있습니다. 또한 자가면역질환의 진단방법 개선을 목적으로 한 프로그램에도 투자하고 있습니다. 기타에도, 누구나 이용하기 쉬운 질 높은 의료 시설을 제공하기 위한 대처도 실시했습니다. 이것은 진단 기술의 현저한 향상과 함께 시장 성장을 강화하고 있습니다. 게다가, 의료 종사자가 보다 종합적인 환자 정보에 접근할 수 있게 되고, 자가면역 질환 진단의 정확성과 신속성을 향상시키기 위해 전자 의료 기록(EMR)의 사용이 증가하고 있습니다. 이것은 원격 의료 채택 증가와 함께 원격자가 면역 질환 진단 및 모니터링 기술 수요를 환기하고 있습니다. 이 외에도 기존의 진단 절차에 비해 고통이 적은 비침습적 진단에 대한 수요가 증가함에 따라 시장에 밝은 전망이 생깁니다.
The global autoimmune disease diagnosis market size reached US$ 3.9 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 6.4 Billion by 2032, exhibiting a growth rate (CAGR) of 5.4% during 2024-2032. The increasing incidences of autoimmune diseases, rising sales of insurance policies, and the growing use of EMRs represent some of the key factors driving the market.
An autoimmune disease is a group of disorders wherein the immune system attacks the cells, tissues, and organs of the body. It can be caused by different medical conditions, such as systemic lupus erythematosus (SLE), multiple sclerosis, rheumatoid arthritis, and type I diabetes. It is associated with fatigue, joint pain and stiffness, skin rashes, fever, and digestive problems. It can also cause damage to organs and tissues, which leads to more severe symptoms like difficulty breathing, organ failure, or even death. It can be diagnosed via a combination of various approaches, such as taking a detailed medical history, performing a physical examination, blood tests to detect specific antibodies, imaging tests to look for damage or inflammation, and a biopsy to examine the affected tissue under a microscope.
The surging incidences of autoimmune diseases among individuals and the increasing aging population that are susceptible to develop such medical conditions represent one of the major factors driving the demand for autoimmune disease diagnosis around the world. Moreover, the rising awareness about autoimmune disease, its symptoms, diagnosis, and the easy availability of the treatment options is favoring the growth of the market. In addition, the growing implementation of health insurance policies that offer financial assistance for autoimmune disease diagnosis or treatment and reduce overall medical expenses is influencing the market positively. Apart from this, governing authorities of several countries are financing research and development (R&D) projects to study autoimmune diseases and develop new treatments. They are also investing in programs that aim to develop improved diagnostic methods for these medical disorders. Besides this, they are undertaking initiatives to offer quality healthcare facilities that are accessible to all. This, coupled with significant improvements in the diagnostic technologies, is strengthening the growth of the market. Furthermore, there is an increase in the use of electronic medical records (EMRs) to improve the accuracy and speed of autoimmune disease diagnosis as healthcare professionals have access to more comprehensive patient information. This, along with the rising adoption of telemedicine is catalyzing the demand for remote autoimmune disease diagnosis and monitoring technologies. Besides this, the growing demand for non invasive diagnosis, which is less painful as compared to traditional diagnostic procedures, is creating a positive outlook for the market.
IMARC Group provides an analysis of the key trends in each sub-segment of the global autoimmune disease diagnosis market report, along with forecasts at the global, regional and country levels from 2024-2032. Our report has categorized the market based on product type, disease type, test type, and end-user.
Consumables and Assay Kits
Instruments
The report has provided a detailed breakup and analysis of the autoimmune disease diagnosis market based on the product type. This includes consumables and assay kits, and instruments. According to the report, consumables and assay kits represented the largest segment.
Systemic Autoimmune Disease
Rheumatoid Arthritis
Psoriasis
Systemic Lupus Erythematosus (SLE)
Multiple Sclerosis
Others
Localized Autoimmune Disease
Inflammatory Bowel Disease
Type 1 Diabetes
Thyroid
Others
A detailed breakup and analysis of the autoimmune disease diagnosis market based on the disease type has also been provided in the report. This includes systemic autoimmune disease (rheumatoid arthritis, psoriasis, systemic lupus erythematosus (SLE), multiple sclerosis, and others) and localized autoimmune disease (inflammatory bowel disease, type 1 diabetes, thyroid, and others). According to the report, localized autoimmune disease (inflammatory bowel disease, type 1 diabetes, thyroid, and others) accounted for the largest market share.
Routine Laboratory Tests
Inflammatory Markers
Autoantibodies and Immunologic Tests
Others
The report has provided a detailed breakup and analysis of the autoimmune disease diagnosis market based on the test type. This includes routine laboratory tests, inflammatory markers, autoantibodies and immunologic tests, and others. According to the report, routine laboratory tests represented the largest segment.
Clinical Laboratories
Hospitals
Others
A detailed breakup and analysis of the autoimmune disease diagnosis market based on the end-user has also been provided in the report. This includes clinical laboratories, hospitals, and others. According to the report, clinical laboratories accounted for the largest market share.
North America
United States
Canada
Asia Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America (the United States and Canada) was the largest market for autoimmune disease diagnosis. Some of the factors driving the North America autoimmune disease diagnosis market included the easy availability of treatments, technological advancements, extensive research and development (R&D) projects, etc.
The report has also provided a comprehensive analysis of the competitive landscape in the global autoimmune disease diagnosis market. Competitive analysis such as market structure, market share by key players, player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided. Some of the companies covered include Abbott Laboratories, AESKU.GROUP, Danaher Corp., bioMerieux SA, Bio-Rad Laboratories, Inc., PerkinElmer Inc., Hemagen Diagnostics, Inc., Inova Diagnostics, Inc., Myriad Genetics, Inc., Quest Diagnostics Incorporated, Siemens Healthineers AG, SQI Diagnostics, Thermo Fisher Scientific Inc., Trinity Biotech plc., etc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.